Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,367 as of Wednesday, March 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,229 issues advancing vs. 1,681 declining with 174 unchanged. The Health Care sector currently sits up 0.1% versus the S&P 500, which is unchanged. Top gainers within the sector include Boston Scientific Corporation ( BSX), up 1.1%, Express Scripts ( ESRX), up 0.9%, Regeneron Pharmaceuticals ( REGN), up 0.8%, Celgene Corporation ( CELG), up 0.7% and AbbVie ( ABBV), up 0.7%. On the negative front, top decliners within the sector include XOMA ( XOMA), down 26.1%, Mylan ( MYL), down 1.9%, Biomarin Pharmaceutical ( BMRN), down 1.8%, Shire ( SHPG), down 1.4% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.3%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Arrowhead Research Corporation ( ARWR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Arrowhead Research Corporation is up $5.03 (23.8%) to $26.17 on heavy volume. Thus far, 4.8 million shares of Arrowhead Research Corporation exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $23.95-$26.88 after having opened the day at $24.06 as compared to the previous trading day's close of $21.14. Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. Arrowhead Research Corporation has a market cap of $796.9 million and is part of the drugs industry. Shares are up 85.1% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Arrowhead Research Corporation a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Arrowhead Research Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Arrowhead Research Corporation Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.